Preliminary clinical data (NCT04930432) on fortnightly intravenous administration of 1,500 mg MCLA-129 in different NSCLC patients were recently published: for patients with METex14 mutation, the ORR was 43.5%, and the DCR was 95.7%; for EGFR20ins-mutated patients, the ORR was 28.6% and DCR of 84.1%; for patients with sensitized EGFR-mutated, ORR was 21.8% and DCR was 69.1% (50). Here, EGFR is linked to non-small cell lung carcinoma.